Real World Experience of Azacitidine + Venetoclax in AML rigorously following management guidelines from clinical trial

Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to VIALE-A study. We report here our single center experience using AZA + VEN rigorously following management guidelines from the VIALE-A study, applied to a real-life population. Forty-two AML patients were analyzed. CR/CRi/MLFS rate was 73,8 % after 1 cycle with 51% CR/CRi and 80,9% after 2 cycles. Median overall survival was 18 months [95% CI, 10.3-25.7]. Our retrospective study showed that rigorous use of AZA + VEN in real-world setting was associated with results close to clinical trial observations. We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in real-world.